Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists

E. Bremer, B. ten Cate, D.F. Samplonius, N. Mueller, H. Wajant, A.J. Stel, M.E.D. Chamuleau, A.A. van de Loosdrecht, J. Stieglmaier, G.H. Fey, W. Helfrich

Research output: Contribution to journalArticleAcademicpeer-review

40 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)597-604
JournalCancer research
Issue number2
Publication statusPublished - 2008

Cite this